FDA Alert
FDA Alert
11/13/2023
Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.
11/13/2023
Addiction
Addiction
02/02/2015
The US Food and Drug Administration has approved the stimulant lisdexamfetamine to treat binge-eating disorder, the first product to be approved for the condition.
02/02/2015